NCT07038941

Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial of Single and Multiple Doses of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Beijing Dayspring Pharmaceutical Technology Co., Ltd · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study is testing CG2001, a new medicine that is applied as a light foam to the scalp and is being developed to treat male-pattern hair loss (androgenetic alopecia). The main goals are to find out: 1. Whether single and repeated daily doses of CG2001 are safe and well-tolerated 2. How much of the drug, if any, enters the bloodstream (pharmacokinetics)

Conditions

• Male Pattern of Hair Loss, Androgenic Alopecia
• Androgenetic Alopecia (AGA)

Interventions

Type	Name	Description
DRUG	CG2001	combination of minoxidil and finasteride
DRUG	Placebo foam	Placebo foam

Timeline

• Start date: 2024-03-19
• Primary completion: 2024-06-02
• Completion: 2024-06-02
• First posted: 2025-06-26
• Last updated: 2025-06-26

Locations

1 site across 1 country: China